Vicki Goodman, M.D., is a physician executive with over two decades of experience in oncology drug development and clinical leadership. She most recently served as Chief Medical Officer at Mural Oncology, where she built and led the development organization and advanced a portfolio of novel cytokine therapies. Prior to that, she was Executive Vice President of Product Development and Medical Affairs and Chief Medical Officer at Exelixis, overseeing early- and late-stage clinical development, regulatory affairs, pharmacovigilance and biometrics across a multi-asset oncology pipeline.
Earlier in her career, Dr. Goodman held senior oncology leadership roles at Merck, Bristol Myers Squibb, and GSK, where she contributed to the development of important oncology medicines, including KEYTRUDA® (pembrolizumab), OPDIVO® (nivolumab), YERVOY® (ipilimumab), and dabrafenib. She began her career as a Medical Officer at the U.S. Food and Drug Administration and has also worked in clinical practice. Dr. Goodman received her M.D. from Albert Einstein College of Medicine and completed her training in internal medicine and hematology/oncology at the University of Michigan.
